TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04120662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary screw fixation
Description: A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused Shock Wave Treatment
Description: 3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
Study: NCT02108197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (S9, ResMed)
Study: NCT01916642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1mg/kg
Description: The total dosage of Etomidate needed for induction of anesthesia is recorded at last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1.5mg/kg
Description: same as other

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2mg/kg
Description: same as other

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2.5mg/kg
Description: same as other
Study: NCT02123277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon catheter for the Eustachian tube
Description: Balloon catheter is inserted in the Eustachian tube to dilate it.
Study: NCT01790022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study: NCT02170467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of the intestinal permeability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of the intestinal permeability
Study: NCT00984061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: 0.6mg tablet administered at 9am on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: 250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: 0.6 mg tablet administered at 9am on Day 29
Study: NCT03343249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Phone Based Smoking Cessation
Description: The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
Study: NCT00657306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 50 mg/6 h per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextrose solution 5%
Description: dextrose solution 5% 100 ml/6 h per day
Study: NCT03121924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: timing for oocyte denudation and Intracytoplasmatic Sperm injection
Description: Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: timing for oocyte denudation and Intracytoplasmatic Sperm injection
Description: Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed.
Study: NCT04764500

Intervention type: OTHER
Intervention: examination of stool sample
Description: Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.

Intervention type: OTHER
Intervention: patient questionnaire
Description: Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.

Intervention type: OTHER
Intervention: examination of blood sample
Description: Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.
Study: NCT05026515

Intervention type: BEHAVIORAL
Intervention: Parents
Description: To observe the influence of the parents/caregivers behavior on their child during dental treatment

Intervention type: BEHAVIORAL
Intervention: Parents
Description: To observe the influence of the parents/caregivers behavior on their child during dental treatment

Intervention type: BEHAVIORAL
Intervention: Parents
Description: To observe the influence of the parents/caregivers behavior on their child during dental treatment
Study: NCT03567720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tavokinogene telseplasmid
Description: Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tavokinogene telseplasmid
Description: Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous 3 weekly treatments

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous 3 weekly treatments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunopulse
Description: Device that administers electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunopulse
Description: Device that administers electroporation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: intravenous on days 1, 8 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine plus carboplatin
Description: intravenous on days 1 and 8 of every 21 days
Study: NCT04130256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle
Description: Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Pill Bottle
Description: Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
Study: NCT02727036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin seed oil
Description: 1 gram capsule of Pumpkin seed oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pumpkin seeds
Description: 4.1 grams (1½ teaspoons/\~0.15ounces) of pumpkin seeds
Study: NCT04403048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Provisional DCB approach PCI procedure
Description: Intervention is explained in detail in group description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard provisional approach PCI procedure
Description: Intervention is explained in detail in group description
Study: NCT03339349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
Study: NCT03432195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System
Study: NCT04963348

Intervention type: OTHER
Intervention: convolutional neural networks (CNNs)
Description: CNN architecture named U-Net architecture
Study: NCT02122081

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo organ-sparing marrow irradiation BID on days -6 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 1-2 hours every 24 hours on days -3 to -2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study: NCT01546597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: * Metformin 500 mg bid on Days 1-5~* Metformin 850 mg bid on Days 6-10~* Metformin 500 mg bid on Days 11-15~* Metformin 850 mg bid on Days 16-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: * Ranolazine 1000 mg bid on Days 11-15~* Ranolazine 1000 mg bid on Days 16-20
Study: NCT02119975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Study: NCT02124759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer
Description: 1.6 g sevelamer + 4.4 g maltodextrin three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: 5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: This is a control group. Maltodextrin, 6 g three times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Fat diet
Description: The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fat diet
Description: The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fat diet
Description: The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Fat diet
Description: The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat diet
Description: The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat diet
Description: The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
Study: NCT03473613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cabergoline
Description: Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Gluconate
Description: Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
Study: NCT01135069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin microsphere 0.1%
Description: Treatment of acne vulgaris

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brand Retin-A Micro tretinoin microsphere gel 0.1%
Description: Treatment of acne vulgaris

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo microsphere gel
Description: treatment of acne vulgaris
Study: NCT01528657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventricular Pace Suppression (Vps)
Description: Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic rhythm support (IRSplus)
Description: All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
Study: NCT04511195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized extract of Sphaeralcea angustifolia
Description: Each patient will be treated topically with a gel containing the Sphaeralcea angustifolia extract three times a day for 4 weeks. Sphaeralcea angustifolia extract is standardized in its active compounds content: Sphaeralcic acid and scopoletin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Gel
Description: Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
Study: NCT03840551

Intervention type: OTHER
Group type: OTHER
Intervention: Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)
Description: The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
Study: NCT00766467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Taken orally once a day in the morning. Dose will change depending upon level of fatigue

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once a day in the morning
Study: NCT03248518

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Information booklet on fatigue which represents usual care in almost all UK rheumatology centres

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Information booklet on fatigue which represents usual care in almost all UK rheumatology centres

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Information booklet on fatigue which represents usual care in almost all UK rheumatology centres

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural approach
Description: A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalised Exercise Programme
Description: PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
Study: NCT03678896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CrewD Program
Description: The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classical structured education
Description: The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
Study: NCT04377464

Intervention type: OTHER
Intervention: SF12, EQ-5D-5L and work status standardized quantitative assessments
Description: Quality of life assessments
Study: NCT02491801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: All arms are given to all participants, in a randomized order
Study: NCT04303936

Intervention type: DEVICE
Group type: OTHER
Intervention: SenseWear® armband device
Description: Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep
Study: NCT02733198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prognosis-guided therapy
Study: NCT03672448

Intervention type: OTHER
Intervention: Naturalistic observation
Description: Naturalistic observation

Intervention type: OTHER
Intervention: Naturalistic observation
Description: Naturalistic observation
Study: NCT04221620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zengar Electroencephalogram (EEG) Neurofeedback device
Description: Electroencephalogram (EEG) Neurofeedback is a noninvasive way to allow the central nervous system to self regulate and calm the brain enough to allow the frontal cortex to function in an ideal state, which is the part of the brain that controls important functions including behavior, problem solving, memory, language, emotions, and judgment. EEG Neurofeedback is performed via a musical medley that lasts for about 34 minutes, with baseline numbers taken at the beginning and after the music finishes. During this time, the participant will wear headphones, sensory clips on the ears (3 total), and two sensors on their head while receiving traditional occupational therapy services.
Study: NCT02117713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001 (Maralixibat)
Description: Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
Study: NCT01096589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Coban 2 (Compression System)
Description: Nonwoven cohesive backing and foam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Coban 2 (Compression System)
Description: Nonwoven cohesive backing and foam.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Coban 2 (Compression System)
Description: Nonwoven cohesive backing and foam.
Study: NCT04527783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
Study: NCT03698630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Sodium Phosphate
Description: Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon\* on the other containing 2 mg dexamethasone.
Study: NCT01096589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comprilan
Description: Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).